Last updated on April 2019

Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients


Brief description of study

The current study is a prospective, randomized, open, multi-center investigation. The aim of the study is to investigate whether the HBeAg seroconversion rate can be improved if applying combination therapy in HBeAg positive CHB patients who has achieved HBVDNA<105copies/mlHBsAg5000IU/ml, ALT 2ULN or Liver histology G2S2.

Detailed Study Description

The HBeAg positive chronic hepatitis B(CHB) subjects who has achieved HBV DNA<10*5copies/mlHBsAg5000IU/ml, ALT 2ULN or Liver histology G2S2 will be randomized to three groups. The subjects who go into group A will be treated by tenofovir disoproxil fumarate (TDF) for 96 weeks; The subjects who go into group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks; The subjects who go into group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.

Clinical Study Identifier: NCT03013556

Find a site near you

Start Over